Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (571-580 of 850) with videos related to

Pageof 85
Sort By:
European Urology Focus|August 13, 2017
Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored TreatmentRoderick van den Bergh, Giorgio Gandaglia, Derya Tilki, et al.
The Journal of Urology|June 19, 2009
Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasiaClaudio Jeldres, Hendrik Isbarn, Umberto Capitanio, et al.
European Urology|April 8, 2017
Local Therapy Improves Survival in Metastatic Prostate CancerSami-Ramzi Leyh-Bannurah, Stéphanie Gazdovich, Lars Budäus, et al.
BMC Cancer|March 3, 2019
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancerCornelia Schroeder, Jan Grell, Claudia Hube-Magg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2007
Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Claudio Jeldres, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
BJU International|February 13, 2010
The presence of prostate cancer on saturation biopsy can be accurately predictedSascha A Ahyai, Hendrik Isbarn, Pierre I Karakiewicz, et al.
BJU International|January 22, 2010
A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinomaSara Baillargeon-Gagné, Claudio Jeldres, Giovanni Lughezzani, et al.
Prostate Cancer and Prostatic Diseases|May 31, 2021
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
Pageof 85

Showing results (571-580 of 850) with videos related to

Sort By:
Pageof 85
European Urology Focus|August 13, 2017
Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored TreatmentRoderick van den Bergh, Giorgio Gandaglia, Derya Tilki, et al.
The Journal of Urology|June 19, 2009
Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasiaClaudio Jeldres, Hendrik Isbarn, Umberto Capitanio, et al.
European Urology|April 8, 2017
Local Therapy Improves Survival in Metastatic Prostate CancerSami-Ramzi Leyh-Bannurah, Stéphanie Gazdovich, Lars Budäus, et al.
BMC Cancer|March 3, 2019
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancerCornelia Schroeder, Jan Grell, Claudia Hube-Magg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2007
Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Claudio Jeldres, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
BJU International|February 13, 2010
The presence of prostate cancer on saturation biopsy can be accurately predictedSascha A Ahyai, Hendrik Isbarn, Pierre I Karakiewicz, et al.
BJU International|January 22, 2010
A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinomaSara Baillargeon-Gagné, Claudio Jeldres, Giovanni Lughezzani, et al.
Prostate Cancer and Prostatic Diseases|May 31, 2021
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
Pageof 85